Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib and Durvalumab in Advanced Bladder Carcinoma
NCT03824691Phase 2Unknown
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Sep 2019
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib and durvalumab in bladder carcinoma, sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Status: unknown.
02
Drugs
cabozantinibdurvalumab
03
Conditions
bladder carcinoma
Beyond the preview
Go deeper on NCT03824691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824691.